Impacto da administração oral de saccharomyces boulardii na imunomodulação e recuperação de pacientes submetidos a ressecção cólica

• Ano de defesa: 2013
• Autor(a) principal: Marcella Lobato Dias
• Tipo de documento: Tese
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Federal de Minas Gerais; UFMG
• Palavras-chave em Português: Probióticos; Translocação bacteriana; Resposta imunológica; Câncer colorretal; Operação gastrointestinal; Complicações infecciosas; Administração oral; Neoplasias colorretais; Cirurgia colorretal; Complicações pós-operatórias; Diarréia; Saccharomyces; Medicina; Antibacterianos/efeitos adversos
• Link de acesso: http://hdl.handle.net/1843/BUBD-9ZGH7R

Probiotics, live microorganisms that confer health benefits to the host when administered in adequate amounts, have been used in humans for many years. Even though many potential health benefits seem to be associated with the use of probiotics, the mechanisms by which these living organisms exert their effects remain unclear. The objective of the current study was to determine the effects of pre-operative administration of probiotics on mRNA expression levels of the following citokynes: IL10, IL1B, IL23A, TNF, IL12B, INFG, IL17A in patients undergoing colorectal surgery. Postoperative infections were also assessed. Thirty three patients undergoing colorectal resection were randomly assigned to 7-day preoperative probiotics (probiotic group, n=15) or conventional (control group, n=18) treatment. Patients who received the probiotic presented with significantly lower mucosa IL1B, IL10 and IL23A mRNA expression than the control group (P=0.001; P=0,04 and P=0,03, respectively). However, IL12B, INFG, IL17A and TNF mRNA expressions did not differ between the two groups (P>0,05). The incidence of postoperative infectious complications was 13.3% and 38.8% in probiotic and control groups, respectively (P>0.05). There was no perioperative mortality in both groups. The median total length of hospital stay was similar between the groups (P>0,05).This study has shown that probiotic treatment with Saccharomyces boulardii can locally downregulate both pro- and anti-inflammatory cytokines, in the intestinal mucosa.